Human PD-1 (Luc) Jurkat Reporter Cell

Cat. No. / Size
Price
Qty
SCJUR-STF064-2Vials (1Vial X 2)
$12410.00
ETA of in-stock products:2 business days

Product Details

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • Description

    The Human PD-1 (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human PD-1 (Uniprot: Q15116), which can use to evaluate the potency of PD-1 blockade. When cocultured with target cells expressing human PD-L1, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 interaction by either anti-PD-1 or anti-PD-L1 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.

  • Application

    • Screen for anti-human PD-1 antagonistic antibody or anti-human PD-L1 antibody.

    • Screen for anti-human PD-1 agonistic antibody.

    PD-1 Assay Principles

  • Growth Properties

    Suspension

  • Selection Marker

    Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)

  • Complete Growth Medium

    RPMI-1640 + 10% FBS

  • Freeze Medium

    Serum-free cell cryopreservation medium

  • Quantity

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • Storage

    Frozen in liquid nitrogen.

  • Mycoplasma Testing

    Negative

  • Sterility Testing

    Negative

  • Instructions for Use

    See data sheet for detailed culturing and assay protocol.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Receptor Assay

     PD-1 FACS

    Expression analysis of human PD-1 on Human PD-1 (Luc) Jurkat Reporter Cell by FACS.
    Cell surface staining was performed on Human PD-1 (Luc) Jurkat Reporter Cell or negative control cell using FITC-labeled anti-human PD-1 antibody.

    Protocol
  • Application

     PD-1 APPLICATION

    Blocking activity of anti-human PD-1 antagonistic antibody (RLU).
    This reporter cell was incubated with serial dilutions of anti-human PD-1 antagonistic antibody in the presence of target cells expressing human PD-L1. The EC50 was approximately 1.189 μg/mL.

    Protocol
  •  PD-1 APPLICATION

    Blocking activity of anti-human PD-1 antagonistic antibody (FOLD).
    This reporter cell was incubated with serial dilutions of anti-human PD-1 antagonistic antibody in the presence of target cells expressing human PD-L1. The max induction fold was approximately 22.47.

    Protocol
  •  PD-1 APPLICATION

    Agonistic activity analysis of anti-human PD-1 agonistic antibody.
    This reporter cell was incubated with serial dilutions of anti-human PD-1 agonistic antibody (Rosnilimab). The EC50 of anti-human PD-1 agonistic antibody (Rosnilimab) is approximately 0.08197 μg/mL.

    Protocol
  • Passage Stability

     PD-1 PASSAGE

    Passage stability analysis by Signaling Bioassay.
    The continuously growing Human PD-1 (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human PD-1 antibody in the presence of target cells expressing human PD-L1. Anti-human PD-1 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 12-36.

    Protocol
*Please contact us if you are interested in related cell pool service.

Customer Reviews
Writing Reviews

Important Statement

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.

Recent Advances

 
Drug Development Progress
  • English Name:

    Programmed cell death protein 1

  • Category:

  • Approved Drugs:

    22 Details

  • Drugs in Clinical Trials:

    193 Details

  • Highest Development Stage:

    Approved

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Important Statement